References
- Al-Azzawi F. Use of the levonorgestrel intrauterine system in postmenopause. Climacteric 2015;18:431–2
- Erkkola R. The contraceptive needs of the perimenopausal woman. Climacteric 2014;17:723–4
- Seeber B, Ziehr SC, Gschlieβer A, et al. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system. Contraception 2012;86:345–9
- Mansour D. Mirena: Pharmacokinetics. http://www.mirena.com/en/professional/indications/contraception/pharmacokinetics/index.php
- American College of Obstetricians and Gynecologists. Committee Opinion. Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism 2013, Number 556
- Backman T, Huhtala S, Tuominen J, et al. Sixty thousand woman-years of experience on the levonorgestrel intrauterine system: an epidemiological survey in Finland. Eur J Contracept Reprod Health Care 2001;6(Suppl 1):23–6
- Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 2003;289:2651–62
- Espeland MA, Shumaker SA, Leng I; WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med 2013;173:1429–36
- Erkkola R, Polo-Kantola P. Oestrogens, cognitive function and dementia. In Erkkola R, ed. The Menopause. Amsterdam: Elsevier, 2006:123–30
- Zandi PP, Carlson MC, Plassman BL, et al. for the Cache County Memory Study Investigators. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 2002;288:2123–9
- Beral V, and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419–27
- Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estradiol-progestogen therapy. Obstet Gynecol 2009;113:65–73
- Backman T, Rauramo I, Jaakkola K, et al. Use of the levonorgestrel-releasing intrauterine system and breast cancer. Obstet Gynecol 2005;106:813–17
- Lyytinen HK1, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well. Int J Cancer 2010;126:483–9
- Soini T, Hurskainen R, Grénman S, Mäenpää J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol 2014;124:292–9
- Guillebaud J, Scott B. Combined hormonal contraception. In Milsom I, ed. Contraception and Family Planning: European Practice of Gynecology and Obstetrics, Vol 8. Amsterdam: Elsevier, 2006:19–55